News

Bioptix Announces Streamlining of Workforce

Bioptix, Inc. (BIOP) (“Bioptix” or the “Company”), announced that on January 14, 2017 the Board of Directors of the Company adopted a plan under which the Company will terminate certain employees associated with the September 2016 acquisition of its subsidiary, Bioptix Diagnostics, Inc.  The Company commenced terminations on January 16, 2017 and terminations are expected to be completed within 30 days.  The Company may pay severance benefits in certain circumstances of up to one month base salary.  The Board determined […]  Read more…


Bioptix Reports Board of Director Changes

Bioptix, Inc. (Nasdaq: BIOP), (the “Company”), announced that Gail Schoettler, Susan Evans and David Welch have resigned from the Company’s Board of Directors. On December 8, 2016, Barry Honig, the beneficial owner of more than ten percent of the outstanding shares of the Company, commenced a legal action in Colorado State court to compel the Company to hold a special meeting of shareholders to, among other items, hold a Director election.  Following commencement of such action, members of the Board of […]  Read more…


Venaxis Reports Name Change to Bioptix, Inc and NASDAQ Ticker Symbol Change to “BIOP” from “APPY”

Trading Change to be Effective December 12, 2016 Boulder, Colo., December 8, 2016 /PRNewswire/ — Venaxis®, Inc. (Nasdaq: APPY), announced that following the approval from shareholders at the 2016 Annual Meeting of Shareholders of the proposal to change the Company’s name, the Company’s name has been changed to Bioptix, Inc and the trading symbol for its Common Shares will change to “BIOP” effective at the opening of trading on December 12, 2016. The Company’s Common Stock trades on the NASDAQ […]  Read more…